Update on vascular disease in systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 15, Issue 5, 2003, Pages 519-527

  Kao, Amy H ^a   Sabatine, Janice M ^a   Manzi, Susan ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b S722 Biomedical Sciences Tower ^*  (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Inflammation; Systemic lupus erythematosus; Vascular disease

Indexed keywords

C REACTIVE PROTEIN; CD40 ANTIGEN; COMPLEMENT;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPLEMENT ACTIVATION; ENDOTHELIUM INJURY; HUMAN; LEUKOCYTE MIGRATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ARTERIOSCLEROSIS; CHRONIC DISEASE; FEMALE; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 0042830780     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200309000-00001     Document Type: Review

References (93)

1. Manzi S, Meilahn EN, Rairie JE, et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415.
2. Esdaile JM, Abrahamowicz M, Grodzicky T, et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337.
3. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
4. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143. This excellent review covers the latest insights into inflammation and atherosclerosis.
5. Libby P: What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001, 88:3J-6J.
6. Mustafa A, Nityanand S, Berglund L, et al.: Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000, 102:2576-2581.
7. Reiss AB, Awadallah NW, Malhotra S, et al.: Immune complexes and IFN-gamma decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res 2001, 42:1913-1922.
8. Bellosta S, Corsini A, Bernini F, et al.: 27-Hydroxycholesterol modulation of low density lipoprotein metabolism in cultured human hepatic and extrahepatic cells. FEBS Lett 1993, 332:115-118.
9. Corsini A, Verri D, Raiteri M, et al.: Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler Thromb Vasc Biol 1995, 15:420-428.
10. Tedesco F, Fischetti F, Pausa M, et al.: Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 1999, 36:261-268.
11. Yasojima K, Schwab C, McGeer EG, et al.: Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001, 158:1039-1051.
12. Niculescu F, Rus HG, Vlaicu R: Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol 1987, 45:147-155.
13. Torzewski M, Klouche M, Hock J, et al.: Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998, 18:369-378.
14. Bhakdi S, Dorweiler B, Kirchmann R, et al.: On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995, 182:1959-1971.
15. Buono C, Come CE, Witztum JL, et al.: Influence of C3 deficiency on atherosclerosis. Circulation 2002, 105:3025-3031. This is a study of the effects of complement C3 deficiency on the extent and phenotype of atherosclerosis.
16. Selzer F, Sutton-Tyrrell K, Fitzgerald S, et al.: Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001, 37:1075-1082.
17. Rodgers GM, Kane WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986, 77:1909-1916.
18. Tsai JC, Perrella MA, Yoshizumi M, et al.: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994, 91:6369-6373.
19. Hajjar KA: Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993, 91:2873-2879.
20. Majors A, Ehrhart LA, Pezacka EH: Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:2074-2081.
21. Upchurch GR Jr, Welch GN, Fabian AJ, et al.: Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997, 272:17012-17017.
22. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775-1781.
23. Ridker PM, Manson JE, Buring JE, et al.: Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999, 281:1817-1821.
24. Stubbs PJ, Al Obaidi MK, Conroy RM, et al.: Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation 2000, 102:605-610.
25. Ridker PM, Shih J, Cook TJ, et al.: Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002, 105:1776-1779. Results of this randomized trial show homocysteine predicts future coronary events but does not help to target statin therapy among those with low to normal LDL cholesterol levels.
26. Petri M, Roubenoff R, Dallal GE, et al.: Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996, 348:1120-1124.
27. Title LM, Cummings PM, Giddens K, et al.: Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000, 36:758-765.
28. Desai-Mehta A, Lu L, Ramsey-Goldman R, et al.: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996, 97:2063-2073.
29. Koshy M, Berger D, Crow MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996, 98:826-837.
30. Kotowicz K, Dixon GL, Klein NJ, et al.: Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology 2000, 100:441-446.
31. Mach F, Schonbeck U, Sukhova GK, et al.: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 1997, 94:1931-1936.
32. Henn V, Slupsky JR, Grafe M, et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
33. Andre P, Prasad KS, Denis CV, et al.: CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002, 8:247-252. This study shows that platelet CD40L is necessary for the stability of arterial thrombi.
34. Mach F, Schonbeck U, Bonnefoy JY, et al.: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997, 96:396-399.
35. Schönbeck U, Mach F, Bonnefoy JY, et al.: Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta. J Biol Chem 1997, 272:19569-19574.
36. Mach F, Schönbeck U, Sukhova GK, et al.: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200-203.
37. Schonbeck U, Varo N, Libby P, et al.: Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266-2268.
38. Boumpas DT, Furie R, Manzi S, et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
39. Kalunian KC, Davis JC Jr, Merrill JT, et al.: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258.
40. Torzewski J, Torzewski M, Bowyer DE, et al.: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998, 18:1386-1392.
41. Pasceri V, Cheng JS, Willerson JT, et al.: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103:2531-2534.
42. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
43. Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194-1197.
44. Nakagomi A, Freedman SB, Geczy CL: Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000, 101:1785-1791.
45. Haverkate F, Thompson SG, Pyke SD, et al.: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349:462-466.
46. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
47. Retterstol L, Eikvar L, Bohn M, et al.: C-reactive protein predicts death in patients with previous premature myocardial infarction - a 10 year follow-up study. Atherosclerosis 2002, 160:433-440.
48. Sakkinen P, Abbott RD, Curb JD, et al.: C-reactive protein and myocardial infarction. J Clin Epidemiol 2002, 55:445-451.
49. Speidl WS, Graf S, Hornykewycz S, et al.: High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002, 144:449-455.
50. Redberg RF, Rifai N, Gee L, et al.: Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol 2000, 36:39-43.
51. Hunt ME, O'Malley PC, Vernalis MN, et al.: C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J 2001, 141:206-210.
52. Folsom AR, Aleksic N, Catellier D, et al.: C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) Study. Am Heart J 2002, 144:233-238.
53. Sitzer M, Markus HS, Mendall MA, et al.: C-reactive protein and carotid intimal medial thickness in a community population. J Cardiovasc Risk 2002, 9:97-103.
54. Wang TJ, Nam BH, Wilson PW, et al.: Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002, 22:1662-1667. This study of an offspring cohort of the Framingham Heart Study indicates a graded association of CRP with carotid atherosclerosis in women but not in men, and underscores the importance of gender-specific analyses.
55. Van DMI, De Maat MP, Hak AE, et al.: C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke 2002, 33:2750-2755. This study demonstrates that CRP predicts progression of subclinical atherosclerosis in different vascular beds using multiple noninvasive measures and that the risk associated with CRP is as high as those associated with more traditional risk factors.
56. Park R, Detrano R, Xiang M, et al.: Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation 2002, 106:2073-2077. This prospective cohort study suggested that nondiabetic individuals and those at intermediate risk might benefit from risk stratification based on high-sensitivity CRP levels and coronary calcium scores.
57. Bickel C, Rupprecht HJ, Blankenberg S, et al.: Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002, 89:901-908. This study demonstrates the antiinflammatory effects of statins.
58. Vaarala O: Autoantibodies to modified LDLs and other phospholipid - protein complexes as markers of cardiovascular diseases. J Intern Med 2000, 247:381-384.
59. Formiga F, Meco JF, Pinto X, et al.: Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001, 10:359-363.
60. Leong KH, Koh ET, Feng PH, et al.: Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994, 21:1264-1267.
61. Wanner C, Rader D, Bartens W, et al.: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993, 119:263-269.
62. Falaschi F, Ravelli A, Martignoni A, et al.: Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000, 43:1405-1409.
63. Borba EF, Santos RD, Bonfa E, et al.: Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994, 21:220-223.
64. Okawa-Takatsuji M, Aotsuka S, Sumiya M, et al.: Clinical significance of the serum lipoprotein(a) level in patients with systemic lupus erythematosus: its elevation during disease flare. Clin Exp Rheumatol 1996, 14:531-536.
65. Sari RA, Polat MF, Taysi S, et al.: Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus. Clin Rheumatol 2002, 21:520-524.
66. Borba EF, Bonfa E, Vinagre CG, et al.: Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1033-1040.
67. Reichlin M, Fesmire J, Quintero-Del-Rio AI, et al.: Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2957-2963. This study raises the possibility that autoantibodies to lipoprotein lipase in patients with SLE may account for elevated triglyceride levels and may contribute to atherosclerosis.
68. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115:243-253.
69. Aviram M, Rosenblat M, Bisgaier CL, et al.: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998, 101:1581-1590.
70. Watson AD, Berliner JA, Hama SY, et al.: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
71. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:473-480.
72. Cuadrado MJ, Tinahones F, Camps MT, et al.: Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. QJM 1998, 91:619-626.
73. George J, Harats D, Gilburd B, et al.: Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 1999, 8:220-226.
74. Craig WY, Poulin SE, Neveux LM, et al.: Anti-oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: relationship with lipopro. J Autoimmun 1995, 8:713-726.
75. Hayem G, Nicaise-Roland P, Palazzo E, et al.: Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001, 10:346-351.
76. Wu R, Svenungsson E, Gunnarsson I, et al.: Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in Systemic lupus erythematosus. Clin Exp Immunol 1999, 115:561-566.
77. Horkko S, Olee T, Mo L, et al.: Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001, 103:941-946.
78. Hasunuma Y, Matsuura E, Makita Z, et al.: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569-573.
79. Muhlestein JB: Bacterial infections and atherosclerosis. J Invest Med 1998, 46:396-402.
80. Vercellotti G: Viruses and atherosclerosis: do they play a pathogenic role? J Invest Med 1998, 46:403-407.
81. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
82. Kiechl S, Lorenz E, Reindl M, et al.: Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192. This study indicates that innate immunity may play a role in atherogenesis.
83. Edfeldt K, Swedenborg J, Hansson GK, et al.: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105:1158-1161. The results of this study suggest a mechanism by which microbes may cause inflammatory plaque activation.
84. Glurich I, Grossi S, Albini B, et al.: Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol 2002, 9:425-432.
85. Ridker PM, Hennekens CH, Stampfer MJ, et al.: Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998, 98:2796-2799.
86. Sorlie PD, Nieto FJ, Adam E, et al.: A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) Study. Arch Intern Med 2000, 160:2027-2032.
87. Siscovick DS, Schwartz SM, Corey L, et al.: Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 2000, 102:2335-2340.
88. Chiu B, Viira E, Tucker W, et al.: Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997, 96:2144-2148.
89. James JA, Neas BR, Moser KL, et al.: Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44:1122-1126.
90. Katz BZ, Salimi B, Kim S, et al.: Epstein-Barr virus burden in adolescents with systemic lupus erythematosus. Pediatr Infect Dis J 2001, 20:148-153.
91. Biasucci LM, Liuzzo G, Angiolillo DJ, et al.: Inflammation and acute coronary syndromes. Herz 2000, 25:108-112.
92. Shah PK: Plaque disruption and thrombosis. Potential role of inflammation and infection. Cardiol Clin 1999, 17:271-281.
93. Plenz G, Robenek H: Monecytes/macrophages in atherosclerosis. Eur Cytokine Netw 1998, 9:701-703.